Surozen exec vice president sells $14,642 worth of stock By Investing.com

In a transaction recently reported to the Securities and Exchange Commission, Surrozen, Inc. (NASDAQ: SRZN ) Research Executive Vice President Li Yang sold 843 shares of common stock. The shares traded at an average price of $17.37, for a total of $14,642. This sale is limited to cover withholding taxes upon issuance of restricted stock units (RSUs). Following this transaction, Young directly owns 13,345 shares. The transaction comes as Surozen, now valued at $55.3 million, has seen its stock rise 44 percent over the past six months. Invest Pro Data shows that analysts have a strong buy rating with significant upside potential.

In addition, Young was granted 2,500 shares of common stock pursuant to vesting RSUs in a transaction dated January 2, 2025. This transaction did not involve any cash exchange as each RSU represents the right to receive one share of Surrozen common stock. As he says Invest ProThe company maintains a good overall financial health score with 10+ additional insights for subscribers.

In other recent news, biotechnology company Surozen Inc. has been actively involved in several significant developments. The company is from TCGFB, Inc. A research collaboration has been entered into, with the aim of antibody treatment for idiopathic pulmonary fibrosis, a serious lung condition. The terms of the partnership include Surozen providing antipersonnel discovery services over a two-year period, with TCGFB retaining all related intellectual property. In return, TCGFB will provide Surozen with up to $6 million in compensation and warrants for up to 3,380,000 shares of TCGFB common stock.

Similarly, Sarrozen has extended its South San Francisco headquarters lease through April 2029, signaling its commitment to maintaining operations in the area. The company is also advancing a successful collaboration with Boehringer Ingelheim with SZN-413, a bi-specific antibody targeted to treat retinal vascular diseases. This development triggered a $10 million payment to Sarrozen, according to their agreement.

The company recently announced the resignation of board member Tim Kutzky, PhD, and reported positive preclinical data for its antibody-specific Wnt mimetic technologies. Additionally, Surrozen has successfully completed a Phase 1a clinical trial for its drug candidate SZN-043. The company received an initial $17.5 million in financing through a private placement agreement, which may have up to $175 million in additional underwriting exercises. These are the latest developments in Cerrozen’s ongoing operations and research efforts.

This article was created by AI Support and reviewed by an editor. See our T&C for more information.